MYGN
HEALTHCAREMyriad Genetics Inc
$4.11-0.92 (-18.29%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MYGN Today?
No stock-specific AI insight has been generated for MYGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.75$8.59
$4.11
Fundamentals
Market Cap$388M
P/E Ratio—
EPS$-4.31
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume7.5M
Avg Volume (10D)—
Shares Outstanding94.4M
MYGN News
20 articles- Myriad Genetics to Participate in Upcoming Investor Healthcare ConferencesYahoo Finance·May 7, 2026
- Myriad Genetics, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Myriad Genetics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%Yahoo Finance·May 5, 2026
- Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum BusinessYahoo Finance·May 5, 2026
- Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To ExpectYahoo Finance·May 4, 2026
- Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care PlanYahoo Finance·Apr 30, 2026
- ProgenyHealth Announces New Appointments to Company Leadership Board and Executive TeamYahoo Finance·Apr 29, 2026
- Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026Yahoo Finance·Apr 28, 2026
- Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out forYahoo Finance·Apr 28, 2026
- 3 Small-Cap Stocks We Think Twice AboutYahoo Finance·Apr 25, 2026
- Tempus AI Expands Strategic Partnership Amid Oncology BoomYahoo Finance·Apr 16, 2026
- Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026Yahoo Finance·Apr 16, 2026
- Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in JapanYahoo Finance·Apr 14, 2026
- 1 Cash-Burning Stock to Target This Week and 2 We QuestionYahoo Finance·Apr 13, 2026
- Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual MeetingYahoo Finance·Apr 9, 2026
- Myriad Genetics And 2 Other Penny Stocks To Watch CloselyYahoo Finance·Apr 6, 2026
- Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics StocksYahoo Finance·Apr 6, 2026
- 3 Healthcare Stocks with Open QuestionsYahoo Finance·Apr 2, 2026
All 20 articles loaded
Price Data
Open$4.70
Previous Close$5.03
Day High$5.06
Day Low$4.69
52 Week High$8.59
52 Week Low$3.75
52-Week Range
$3.75$8.59
$4.11
Fundamentals
Market Cap$388M
P/E Ratio—
EPS$-4.31
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume7.5M
Avg Volume (10D)—
Shares Outstanding94.4M
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—